MedTrace Logo

Wumeiwan Jiawei Fang Use in Patients With Blepharospasm

NCT05618470 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2022-11-17

No results posted yet for this study

Summary

To evaluate the efficacy and safety of Jing Fang Wu Mei Wan Jiawei Fang in the treatment of idiopathic blepharospasm using a clinical randomized controlled trial method.

Conditions

  • Dry Eye Syndromes
  • Meige Syndrome
  • Blepharospasm
  • Hyperactivity

Interventions

DRUG

Wumeiwan Jiawei Fang

orally administered Wumeiwan Jiawei Fang prescription granules, 1 dose a day, twice a day, once for 14 days, for 42 days.

DRUG

botulinum toxin A

Botulinum toxin (Lanzhou Biopharmaceutical Co., LTD.) was injected into the medial side of the upper eyelid, the lateral side of the upper eyelid, the lateral side of the lower eyelid, and the temporal orbicularis oculi muscle of the lateral canthus. The botulinum toxin type A was diluted into 50IU/ML with normal saline and injected with a 1ml skin test syringe (4\\ 5-gauge needle), and 2.5IU was injected into each point. A total of 1 injection.

Sponsors & Collaborators

  • China Academy of Chinese Medical Sciences

    lead OTHER

Principal Investigators

  • wei yang · China Academy of Chinese Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-12
Primary Completion
2024-08-30
Completion
2024-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05618470 on ClinicalTrials.gov